M 3814

Drug Profile

M 3814

Alternative Names: M-3814; MSC-2490484A; Nedisertib

Latest Information Update: 22 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; Merck KGaA
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Small cell lung cancer
  • Phase I Chronic lymphocytic leukaemia; Solid tumours

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase Ia/Ib trial in Solid tumors presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASC0-2018)
  • 05 Jan 2018 EMD Serono and MerckKGaA terminate a phase II trial in Small cell lung cancer in USA due to low rate of enrolment and change in focus of the study
  • 29 Jun 2017 Merck completes a phase I trial in Solid tumours and Chronic lymphocytic leukaemia (Late-stage disease) in Germany (PO) (NCT02316197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top